[{"id":"757c7ea9-28ea-4973-bbc9-a09748839d13","acronym":"","url":"https://clinicaltrials.gov/study/NCT05039801","created_at":"2021-09-10T16:57:15.373Z","updated_at":"2025-02-25T15:35:16.395Z","phase":"Phase 1","brief_title":"IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors","source_id_and_acronym":"NCT05039801","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • PIK3CA • PTEN • STK11 • ARID1A • NF1 • KEAP1 • PD-1 • NFE2L2","pipe":" | ","alterations":" PIK3CA mutation • ARID1A mutation • STK11 mutation • KEAP1 mutation • NFE2L2 mutation","tags":["PD-L1 • PIK3CA • PTEN • STK11 • ARID1A • NF1 • KEAP1 • PD-1 • NFE2L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • ARID1A mutation • STK11 mutation • KEAP1 mutation • NFE2L2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • paclitaxel • Truqap (capivasertib) • IPN60090"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 09/09/2021","start_date":" 09/09/2021","primary_txt":" Primary completion: 05/29/2026","primary_completion_date":" 05/29/2026","study_txt":" Completion: 05/29/2026","study_completion_date":" 05/29/2026","last_update_posted":"2025-02-10"},{"id":"d8999917-3c0d-4b22-aa4a-6a2e1a2de773","acronym":"TRITON","url":"https://clinicaltrials.gov/study/NCT06008093","created_at":"2023-08-23T15:11:10.888Z","updated_at":"2025-02-25T16:55:15.589Z","phase":"Phase 3","brief_title":"A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients","source_id_and_acronym":"NCT06008093 - TRITON","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • KRAS • ALK • STK11 • KEAP1","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • STK11 mutation • ALK fusion • KEAP1 mutation","tags":["EGFR • KRAS • ALK • STK11 • KEAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • STK11 mutation • ALK fusion • KEAP1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • pemetrexed"],"overall_status":"Recruiting","enrollment":" Enrollment 280","initiation":"Initiation: 04/04/2024","start_date":" 04/04/2024","primary_txt":" Primary completion: 08/17/2027","primary_completion_date":" 08/17/2027","study_txt":" Completion: 03/20/2031","study_completion_date":" 03/20/2031","last_update_posted":"2025-02-04"},{"id":"92435528-4415-4d93-8e63-2a53a10bdf30","acronym":"","url":"https://clinicaltrials.gov/study/NCT04250545","created_at":"2021-01-18T20:39:21.304Z","updated_at":"2024-07-02T16:34:58.880Z","phase":"Phase 1","brief_title":"Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04250545","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • BRAF • ALK • ROS1 • KEAP1 • NFE2L2","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • BRAF V600K • KEAP1 mutation • NFE2L2 mutation","tags":["KRAS • BRAF • ALK • ROS1 • KEAP1 • NFE2L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • BRAF V600K • KEAP1 mutation • NFE2L2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sapanisertib (CB-228) • telaglenastat (CB-839)"],"overall_status":"Recruiting","enrollment":" Enrollment 85","initiation":"Initiation: 10/26/2020","start_date":" 10/26/2020","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-06-04"},{"id":"7315975a-48e7-478f-a922-63b5c722e7c1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03872427","created_at":"2021-01-18T19:05:39.832Z","updated_at":"2024-07-02T16:35:03.365Z","phase":"Phase 2","brief_title":"Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study","source_id_and_acronym":"NCT03872427","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" STK11 • NF1 • KEAP1 • NFE2L2","pipe":" | ","alterations":" STK11 mutation • NF1 mutation • KEAP1 mutation • NFE2L2 mutation","tags":["STK11 • NF1 • KEAP1 • NFE2L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STK11 mutation • NF1 mutation • KEAP1 mutation • NFE2L2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e telaglenastat (CB-839)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 12/14/2019","start_date":" 12/14/2019","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 08/31/2024","study_completion_date":" 08/31/2024","last_update_posted":"2024-05-16"},{"id":"64165b3f-b55d-41f6-83d8-fad55beb1590","acronym":"","url":"https://clinicaltrials.gov/study/NCT05275868","created_at":"2022-03-11T14:53:23.220Z","updated_at":"2024-07-02T16:35:17.689Z","phase":"Phase 1","brief_title":"Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05275868","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" KEAP1 • NFE2L2","pipe":" | ","alterations":" KEAP1 mutation • NFE2L2 mutation","tags":["KEAP1 • NFE2L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KEAP1 mutation • NFE2L2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGY825"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 10/05/2022","start_date":" 10/05/2022","primary_txt":" Primary completion: 08/17/2026","primary_completion_date":" 08/17/2026","study_txt":" Completion: 08/17/2026","study_completion_date":" 08/17/2026","last_update_posted":"2024-02-26"},{"id":"49802c3e-ce1e-4e25-99ea-df4984c5d29c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05276726","created_at":"2022-03-11T14:53:34.119Z","updated_at":"2024-07-02T16:36:03.348Z","phase":"Phase 1/2","brief_title":"A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1","source_id_and_acronym":"NCT05276726","lead_sponsor":"Jacobio Pharmaceuticals Co., Ltd.","biomarkers":" KRAS • STK11 • KEAP1","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • STK11 mutation • KEAP1 mutation • KRAS G12","tags":["KRAS • STK11 • KEAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • STK11 mutation • KEAP1 mutation • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Airuikai (glecirasib)"],"overall_status":"Recruiting","enrollment":" Enrollment 104","initiation":"Initiation: 08/17/2022","start_date":" 08/17/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2022-09-28"},{"id":"8ae6d248-ecbb-408f-8f2f-48c143b00eec","acronym":"","url":"https://clinicaltrials.gov/study/NCT02417701","created_at":"2021-01-17T17:54:54.823Z","updated_at":"2024-07-02T16:36:13.984Z","phase":"Phase 2","brief_title":"Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer","source_id_and_acronym":"NCT02417701","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • KEAP1 • NFE2L2 • CD4","pipe":" | ","alterations":" KRAS mutation • KEAP1 mutation • NFE2L2 mutation","tags":["KRAS • KEAP1 • NFE2L2 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KEAP1 mutation • NFE2L2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sapanisertib (CB-228)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 10/06/2016","start_date":" 10/06/2016","primary_txt":" Primary completion: 12/28/2020","primary_completion_date":" 12/28/2020","study_txt":" Completion: 12/28/2020","study_completion_date":" 12/28/2020","last_update_posted":"2022-04-05"},{"id":"2d1fef42-d797-428a-8f56-db28088ee549","acronym":"ECOG-ACRIN LUNG-MAP Sub-Study","url":"https://clinicaltrials.gov/study/NCT04267913","created_at":"2021-01-18T20:44:15.415Z","updated_at":"2024-07-02T16:36:38.345Z","phase":"Phase 2","brief_title":"Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)","source_id_and_acronym":"NCT04267913 - ECOG-ACRIN LUNG-MAP Sub-Study","lead_sponsor":"Southwest Oncology Group","biomarkers":" KEAP1 • NFE2L2 • CD4","pipe":" | ","alterations":" KEAP1 mutation • NFE2L2 mutation","tags":["KEAP1 • NFE2L2 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KEAP1 mutation • NFE2L2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Cyramza (ramucirumab) • sapanisertib (CB-228) • dexamethasone injection • lexatumumab (ETR2-ST01)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/05/2020","start_date":" 09/05/2020","primary_txt":" Primary completion: 10/31/2025","primary_completion_date":" 10/31/2025","study_txt":" Completion: 10/31/2026","study_completion_date":" 10/31/2026","last_update_posted":"2020-11-20"}]